Clinical Trials
Since 2000, TTC has been a member of the National Institute of Drug Abuse’s (NIDA) Clinical Trials Network, which aims to bridge the gap between research and practice in the field of addiction.
For more information about trials and for enrollment, please call 818-996-1051, x1310.
Current Trials
Treatment-as-Usual Opioid Use Outcomes Following Discharge
Tarzana Treatment Centers is 1 of 6 national sites conducting an observational study (CTN-0051-A2) which will describe opioid use among opioid use disorder patients following their discharge into the community from inpatient detoxification and/or short-term residential treatment programs. Up to 60 participants will be enrolled while in Detox, and will complete follow-ups at weeks 1, 4, and 8 after discharge.
Completed Trials
X:BOT CTN-0051 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (Enrollment closed May, 2016)
TTC enrolled over 90 individuals in this Study and additionally, after the 6 month treatment period, connected those who were interested with Medication Assisted Treatment (MAT) programs. TTC is one of 8 national sites assessing the comparative effectiveness of extended release injectable naltrexone (Vivitrol) versus buprenorphine-naloxone (Suboxone) as an aid to recovery amongst treatment-seeking heroin and/or prescription opioid dependent participants admitted to our inpatient detox program. The primary goal of the study is to estimate the difference, if one exists, between Vivitrol and Suboxone in the time to relapse during a 6 month trial in outpatient treatment.